Head to Head Analysis: BetterLife Pharma (OTCMKTS:BETRF) versus Aldeyra Therapeutics (NASDAQ:ALDX)

BetterLife Pharma (OTCMKTS:BETRF) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares BetterLife Pharma and Aldeyra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BetterLife Pharma	N/A	N/A	-618.31%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Institutional & Insider Ownership

0.0% of BetterLife Pharma shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 34.8% of BetterLife Pharma shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares BetterLife Pharma and Aldeyra Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BetterLife Pharma	N/A	N/A	-$1.07 million	N/A	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85 million	($0.46)	-3.87

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BetterLife Pharma and Aldeyra Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BetterLife Pharma	0	0	0	0	0.00
Aldeyra Therapeutics	1	2	1	0	2.00

Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 208.99%. Given Aldeyra Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than BetterLife Pharma.

Volatility & Risk

BetterLife Pharma has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Summary

Aldeyra Therapeutics beats BetterLife Pharma on 6 of the 9 factors compared between the two stocks.

About BetterLife Pharma

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.